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Increased numbers of peripheral blood mononucleocytes (PBMC) and increased IFN-γ
secretion following in vitro challenge of blood samples with soluble Leishmania antigen
(SLA), have been proposed as biomarkers of specific cell-mediated immunity, indicating
that treatment of visceral leishmaniasis (VL) has been successful. However, Leishmania
infantum infection may manifest as cutaneous leishmaniasis (CL), and less commonly
as localized leishmanial lymphadenopathy (LLL) or mucosal leishmaniasis (ML). The
present work examines the value of these biomarkers as indicators of cured leishmaniasis
presenting in these different forms. Blood samples were collected before and after
treatment from patients living in Fuenlabrada (Madrid, Spain), an L. infantum-endemic
area recently the center of a leishmaniasis outbreak. All samples were subjected
to Leishmania-specific PCR, serological tests (IFAT and rK39-ICT), and the SLA-cell
proliferation assay (SLA-CPA), recording PBMC proliferation and the associated changes
in IFN-γ production. Differences in the results recorded for the active and cured conditions
were only significant for VL. PCR returned positive results in 67%of patients with active VL
and in 3% of those with cured leishmaniasis. Similarly, rK39-ICT returned a positive result
in 77% of active VL samples vs. 52% in cured VL samples, and IFAT in 90% vs. 56%; in
the SLA-CPA, PBMC proliferation was seen in 16% vs. 90%, and an associated increase
in IFN-γ production of 14 and 84%, respectively. The present findings reinforce the
idea that PBMC proliferation and increased IFN-γ production in SLA-stimulated PBMC
provide biomarkers of clinical cure in VL. Other tests are urgently needed to distinguish
between the cured and active forms of the other types of clinical leishmaniasis caused
by L. infantum.
Keywords: visceral leishmaniasis, cutaneous leishmaniasis, lymphadenopathic leishmaniasis, mucosal
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INTRODUCTION
A Wide Spectrum of Clinical Forms
Produced by L. infantum
Leishmaniasis is a neglected, vector-borne disease with high
morbidity caused by protozoan pathogens of the genus
Leishmania. Over 350 million people in some 98 countries are
at risk, and an estimated 1.3 million new cases of leishmaniasis
are reported every year (WHO, 2010).
Infection with Leishmania infantum is manifested in different
clinical forms. The most severe is visceral leishmaniasis (VL),
in which the parasite is systemically disseminated; it is fatal if
untreated. Cutaneous leishmaniasis (CL) is a benign form caused
by the multiplication of Leishmania in the skin; these infections
usually clear up spontaneously. Both these clinical forms are
seen in Mediterranean countries. During the L. infantum-
caused outbreak of leishmaniasis in Fuenlabrada (Madrid,
Spain), VL was seen in about a third of people with clinical
infection, and CL in most of the remainder (Suárez Rodríguez
et al., 2012; Arce et al., 2013); a small number presented
with mucosal leishmaniasis (ML) and leishmanial localized
lymphadenopathy (LLL). LLL is characterized by long term
lymphadenopathy with neither fever nor any other systemic
symptom (Horrillo et al., 2015). These differences in the clinical
presentation of the disease seem mainly attributable to the
patient’s immune status. Certainly, the molecular typing of L.
infantum isolates from patients in Fuenlabrada revealed no
association between genotype and disease type (Chicharro et al.,
2013).
Biomarkers Are Needed That Can Identify
Cured Patients Following Treatment for
Leishmaniasis
Treatment for leishmaniasis is usually effective, but relapses
are common, especially in immunosuppressed patients (van
Griensven et al., 2014). Confirmation of a final cure in both
CL and VL is still based on clinical features after follow-
up periods of 6 months; relapses commonly occur long after
treatment has ended (Rijal et al., 2013). In immunocompetent
patients with VL, a successful response to therapy depends on
the activation of a Th1 subset of CD4+ Leishmania-specific T
cells, and the production of IFN-γ, which induces macrophage
leishmanicidal activity (Kemp et al., 1993). Indeed, the
proliferation of blood mononucleocytes (PBMC) after challenge
with soluble leishmanial antigen (the soluble Leishmania antigen
cell proliferation assay [SLA-CPA]) (Singh and Sundar, 2014;
Carrillo et al., 2015), and increased IFN-γ secretion by these cells
(Hailu et al., 2004; Kumar et al., 2014), provide in vitro markers
that might be used to assess early response to treatment. In fact,
PBMC proliferation has been shown a useful indicator of the
existence of Leishmania-specific T cell memory clones in HIV+
patients, sufficient to keep the parasitic infection under control
and avoid relapsing VL (Castro et al., 2016). The value of IFN-γ
in monitoring the cellular immune response has previously been
reported in VL caused by L. infantum (Cillari et al., 1995; Adem
et al., 2016; Ibarra-Meneses et al., 2017).
The present work examines the value of these biomarkers
and others as indicators of cured leishmaniasis presenting in its
different forms; their sensitivity and specificity have been said
to vary across the different manifestations of the disease (Kip
et al., 2015). The results confirm that PBMC proliferation and
increased IFN-γ production following the challenge of blood
samples with SLA, can be used to identify patients cured of VL.
However, new biomarkers are required that are able to indicate
the same in the other forms of L. infantum-induced disease.
MATERIALS AND METHODS
Study Group, Blood Samples, and Tests
Performed
The study subjects were 141 adult patients from Fuenlabrada
(Madrid, Spain). All were diagnosed at the Hospital Universitario
de Fuenlabrada between January 2013 and June 2015. Blood
samples were collected during the period of active disease
and after apparent cure. Active VL, CL, and ML was defined
according toWHO definitions (WHO, 2010). LLL was defined as
isolated adenopathy with no other systemic symptom (Ignatius
et al., 2011; Horrillo et al., 2015). Blood samples were obtained
from 33 patients with active VL, 27 from those with active CL,
6 from those with active LLL, and 2 from those with active
ML. Post-supposed-cure blood samples were available from 61
patients originally diagnosed with active VL, 41 with CL, 21
with LLL, and 3 with ML, with cure defined as being free of
leishmaniasis symptoms 6 months after the end of treatment
(WHO, 2010). None of the cured patients has relapsed after 2
further years of follow-up.
All samples were analyzed by Leishmania-specific nested PCR
to detect leishmanial DNA. Leishmania-specific antibodies were
determined in plasma using the rK39 immunochromatographic
test (rK39-ICT) and immunofluorescent antibody test (IFAT).
PBMC proliferation after stimulation with SLA was measured
(SLA-CPA assay), and the accompanying production of IFN-γ
recorded.
DNA Extraction and Nested PCR
Genomic DNA was extracted from 100 µl of peripheral blood
using the QIAamp DNA Mini Kit (Qiagen, Germany) following
the manufacturer’s recommendations, and eluted in a final
volume of 200 µl of PCR-grade water. The extracts were stored
at 4◦C until PCR analysis (maximum of 3 days). Leishmania
DNA was detected by nested PCR (LnPCR), targeting the small
subunit ribosomal ribonucleic acid gene SSU-rRNA (18S RNA).
A first amplification step was performed using primers R221 and
R332 (van Eys et al., 1992); the PCR product was then tested in
a subsequent amplification step with primers R233 and R333, as
described by Cruz et al. (2002).
Immunofluorescent Antibody Test
2 × 105 L. infantum promastigotes (JPC strain MCAN/ES/
98/LLM-722) in PBS were fixed to glass slides. Two-fold serial
dilutions of plasma—from 1/20 to 1/640 in PBS—were then
added to separate preparations. The total IgG concentration
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was then determined by adding fluorescein isothiocyanate-
conjugated goat anti-human IgG (Fluoline G) (Bio-Mérieux,
France) diluted 1/200. The threshold titre for positivity was set
at the 1/80 plasma dilution level.
rK39 Immunochromatographic Test
Antibody detection was performed using the dipstick format
Kalazar Detect Rapid Test (InBIOS International, Seattle, WA)
according to the manufacturer’s instructions.
Preparation of Soluble L. infantum Antigen
for SLA-CPA
L. infantum antigen extract was prepared from stationary phase
promastigote cultures (JPC strain, MCAN/ES/98/LLM-722) as
previously described (Carrillo et al., 2015). Briefly, parasites
resuspended in lysis buffer (50mM Tris/5mM EDTA/HCl, pH
7) were subjected to three rapid freeze/thaw cycles followed by
three 20 s 40W pulses with a sonicator. These samples were then
subjected to two consecutive rounds of centrifugation at 27,000
g and 4◦C for 20min. The supernatants were then collected,
aliquoted, and stored at −80◦C until use. Protein quantification
was performed using the Bradford method employing the Bio-
Rad Protein Assay Kit (Bio-Rad, California, USA).
SLA-Cell Proliferation Assay (SLA-CPA)
PBMC were isolated by density centrifugation through Ficoll-
Hypaque (Rafer, Spain). The collected cells were cultured in
RPMI 1640 supplemented with 10% heat-inactivated fetal bovine
serum, 100 IU/ml penicillin, 100µg/ml streptomycin, 2mM
L-glutamine, 50µM 2-mercaptoethanol, and 1mM sodium
pyruvate. They were then plated in 96 well-plates and kept
with RPMI 1640 medium alone (unstimulated) or with added
SLA (10µg/ml). All were kept in a humidified, 5% CO2
atmosphere at 37◦C for 5 days. Cell proliferation was measured
by bromodeoxyuridine incorporation using the Cell Proliferation
Biotrak ELISA Kit (General Electric Healthcare Life Sciences,
UK). The results are shown as a stimulation index (SI).
Cytometric Quantification of IFN-γ
IFN-γ production was determined in 50 µl of the supernatants
from the above SLA-stimulated and control PBMC cultures
using the BD Cytometric Bead Array Human Flex Set
(Beckton Dickinson Biosciences, New Jersey, USA), as previously
described (Carrillo et al., 2015). Supernatants were collected
and stored at −20◦C for cytokine analysis. Data were acquired
using a FACSCalibur flow cytometer and analyzed using the
Flow Cytometric Analysis Program Array (Beckton Dickinson
Biosciences, New Jersey, USA). IFN-γ production was expressed
(in pg/ml) as the difference between the concentration in SLA-
stimulated and control supernatants.
Statistical Analysis
Statistical analyses were performed using the SPSS package
(Chicago, IL, USA) or GraphPad Prism 7.0 software (GraphPad
Software, CA, USA). Cut-offs were determined by calculating
the area under the receiver operating characteristic (ROC) curve
(AUC) and the 95% confidence interval (CI). Values for variables
recorded before and after treatment were compared using the
Mann–Whitney U-test. Significance was set at p < 0.05.
RESULTS AND DISCUSSION
The Parasitological and Serological Tests
Identified Cured VL, but Not Cured CL,
LLL, or ML
The results of the PCR (in particular), rK39-ICT and IFAT
tests for active and cured VL were significantly different, thus
identifying the cured condition (Table 1).
In contrast, PCR detected parasite DNA in very few CL, LLL
or ML blood samples with no significant differences recorded
between the active and cured conditions. Similarly, the rk39-ICT
and IFAT tests returned very similar results for the active and
cured forms of these disease presentations (Table 1).
Cell-Mediated Immunity: PBMC
Proliferation and IFN-γ Production as
Biomarkers of Cured VL
Analysis of cell-mediated immunity in the different clinical
conditions revealed significant differences between active and
cured conditions only for VL (Table 1): indeed, most of the
patients with active VL showed no Leishmania-specific cell-
mediated immunity, but did so after effective treatment, with
TABLE 1 | Percentage of positive results returned by parasitological, serological, and cellular immunity tests, in patients with active (A) and cured (C) leishmaniasis.
Clinical condition PCR (%) rK39 (%) IFAT (%) SLA-CPA (%)a IFN-γ (%)b
A C A C A C A C A C
Visceral leishmaniasis 67 3*** 77 52* 90 56* 16 90**** 14 84****
Cutaneous leishmaniasis 4 2 4 2 0 2 33 56 31 62
Leishmanial lymphoadenopathy 0 0 33 43 33 14 52 67 47 75
Mucosal leishmaniasis 0 0 100 67 50 67 33 100 33 100
aThe stimulation index cut-offs for SLA-CPA (ROC curve) were = 2.53 for VL, 2.26 for CL, 3.16 for LLL, and 4.23 for ML.
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FIGURE 1 | Proliferation of PBMC (SLA-CPA) (A,C,E,G) and associated IFN-γ
production (B,D,F,H) from active and cured patients with different clinical
forms of L. infantum-induced disease. ****p < 0.0001. AVL, Active Visceral
Leishmaniasis; CVL, Cured Visceral Leishmaniasis; ACL, Active Cutaneous
Leishmaniasis; CCL, Cured Cutaneous Leishmaniasis; ALLL, Active
Leishmanial Localized Lymphadenopathy; CLLL, Cured Leishmanial Localized
Lymphadenopathy; AML, Active Mucosal Leishmaniasis; CML, Cured Mucosal
Leishmaniasis.
PBMC proliferation confirmed (Figure 1A, p< 0.0001) and IFN-
γ levels increased (Figure 1B, p < 0.0001) (cut-offs: Stimulation
index = 2.53; IFN-γ = 133.4 pg/ml). No such conversion was
seen in any other disease presentation type (Figures 1C–H).
Lack of Surrogate End-Points to Define
Cure in Leishmaniasis
A confirmation of cure has traditionally been based on clinical
features, such as the normalization of body temperature, a
reduction in the size of the liver and spleen, and an increase
in peripheral blood leukocytes, hemoglobin and platelets in VL,
or the healing of lesions in CL. However, observations have to
be made over long follow-up times since relapses may occur
long after treatment ends. Unfortunately, PCR and serological
tests are not good indicators of cure (WHO, 2017). PCR detects
parasites in active VL, but after the first doses of treatment their
numbers can fall dramatically (Castro et al., 2016) while clinical
manifestations of disease remain. Further, the non-detection of
peripheral blood parasites does not necessarily mean that the
spleen, liver, or bonemarrow are parasite-free, whichmight allow
for the reactivation of clinical disease months later, as repeatedly
reported in immunosuppressed patients (van Griensven et al.,
2014). PCR results on their own cannot, therefore, provide a
reliable marker of cure. Neither can serological tests (rK39-ICT
and IFAT) be used to identify cure: antibodies are present in
active VL but persist long after cure (Hailu et al., 2004; WHO,
2010).
Cell-Mediated Immunity Tests for
Monitoring Treatment
The development of solid cell-mediated immunity rendering
patients resistant to reinfection only occurs after successful
treatment and the start of healing (Kemp et al., 1993; Kumar
et al., 2014). Early monitoring of response to treatment (for both
VL and CL) therefore requires specific biomarkers be identified
that correlate with the development of this immunity (WHO,
2017). PBMC proliferation and increased IFN-γ production
upon stimulation with SLA are expressions of this immunity,
and can be easily and repeatedly evaluated ex vivo without
patient sensitization (Carrillo et al., 2015). In addition, these
two biomarkers have added value in terms of allowing a “no
relapse” prognosis to be made: both are directly associated with
the immunological control of the parasite and the absence of
reactivation. By way of comparison, while PCR can confirm
parasite elimination in blood, it cannot predict whether the
disease might be reactivated by cryptic parasites in the target
organs.
The appearance of cell-mediated immunity after successful
treatment has also been reported for Leishmania donovani
(WHO, 2017). PBMC proliferation and an associated increase in
IFN-γ production upon the stimulation of blood samples with
SLAmight therefore provide global markers of cure in VL (Adem
et al., 2016; Castro et al., 2016). Our group has already shown that
a patent cell proliferative response remains long after treatment,
that it is useful for monitoring disease in immunosuppressed
patients with VL (Castro et al., 2016), and that it is associated
with a lack of relapse (Hailu et al., 2004; Singh and Sundar, 2014).
Lack of Biomarkers for Identifying Cure in
CL, LLL, and ML
The present results show that none of the tests examined could
distinguish between active disease and cure in CL, LLL, or ML.
In fact, many patients with CL and LLL returned positive SLA-
CPA results (i.e., PBMC proliferation) before treatment, revealing
an active cell-mediated immune response to be underway. The
same response has been described in patients with active CL
caused by L. major, which appears to be associated with the
spontaneous healing of the lesion. In active CL, a lack of PBMC
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proliferation and low IFN-γ production (together with IL-4
production) following SLA challenge in vitro has been associated
with severe disease and a lack of healing (Gaafar et al., 1995;
Ajdary et al., 2000).
The mean stimulation index values recorded after SLA
challenge shows the cell-mediated immune response against
Leishmania to be strongest in patients cured of VL. Differences
in this response between patients cured of VL and CL
have been reported previously, and might reflect a stronger
systemic Th-1 response to occur in the former given the
need to clear a much heavier parasite burden (Turgay et al.,
2010; Alimohammadian et al., 2012). The patients with
LLL—perhaps an evolved form of CL—showed the strongest
immunological response before treatment, with Leishmania
parasites present in affected lymph glands near the site of
the Phlebotomus bite (Horrillo et al., 2015). The intense
immunological activity in lymph nodes probably results in
an immune over-reaction against the parasite. No information
on the immunological features of LLL has previously been
reported.
The present study suffers from the limitation of the imbalance
in patient numbers between the groups; indeed, the numbers
of patients with active ML and LLL are too small to be able to
draw safe conclusions. To our knowledge, however, this is the
first time that the immune response of such a large number
of individuals with different clinical forms of disease caused
by L. infantum, and all from the same endemic area, has been
examined.
Individual differences in the immune response to L. infantum
result in different clinical outcomes. The absence of a specific
cell-mediated response to the parasite in patients with active
VL allows in vitro SLA-activated PBMC proliferation and the
associated increase in IFN-γ production—all of which occurs
after successful treatment—to act as biomarkers of cure in this
disease type. Their use might improve patient follow-up and
reduce the cost of clinical trials of VL treatments. In patients with
active CL, LLL, and ML, the cell-mediated response observed
in a large number of patients seems capable of preventing the
spread of the parasite to the internal organs, but it provides no
indicator of cure since there are no differences before and after
treatment. Biomarkers of cure of CL, LLL, and ML are, therefore,
still needed.
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